{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:16:56Z","timestamp":1753877816798,"version":"3.41.2"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":330,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Relevant information about vaccination history, tuberculosis exposure and other infectious risks were collected through blood sampling, complete anamnesis, chest X-ray and Mantoux test. During the ImmunoStart consultation, vaccination schedules, specific treatments and risk considerations were discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between October 2016 and February 2020, 437 patients were seen at an ImmunoStart consultation, mainly referred by rheumatologists (56%), dermatologists (25%) and gastroenterologists (18%). A total of 421 (96%) patients needed at least one vaccine (a mean of 3.3 vaccines per patient). Live attenuated vaccine was indicated for 45 patients (10%), requiring them to reduce or interrupt their immunosuppressive drug(s). Ninety-two patients (21%) were treated for latent tuberculosis infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This preventive consultation provides a centralized and systematic setting for the direct management of patients with IMID in need of vaccination, treatment of latent disease and specific advice regarding their immunomodulating treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab092","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T08:18:26Z","timestamp":1638346706000},"source":"Crossref","is-referenced-by-count":3,"title":["ImmunoStart: preparing patients for immunosuppression"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-6230","authenticated-orcid":false,"given":"Charlotte","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinciane","family":"Muls","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Brasseur","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Meric de Bellefon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan-Lan","family":"Lam Hoai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre Hospitalier Universitaire (CHU) Saint-Pierre\u2013Universit\u00e9 Libre de Bruxelles (ULB), Brussels"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Vanderhilst","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immune Pathology, Jessa Hospital, Limburg Clinical Research Center, University of Hasselt, Hasselt, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Di Romana","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"2021121109425183300_rkab092-B1","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"2021121109425183300_rkab092-B2","first-page":"216","article-title":"Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study","volume":"33","author":"Lampropoulos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2021121109425183300_rkab092-B3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2021121109425183300_rkab092-B4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jama.1992.03480090085032","article-title":"Severe measles in immunocompromised patients","volume":"267","author":"Kaplan","year":"1992","journal-title":"JAMA"},{"key":"2021121109425183300_rkab092-B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"author":"Belgian guidelines on the diagnosis and management of latent tuberculosis infection","key":"2021121109425183300_rkab092-B6"},{"key":"2021121109425183300_rkab092-B7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.rhum.2013.08.004","article-title":"Conseils d\u2019utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellis\u00e9es par la Haute Autorit\u00e9 de sant\u00e9 fran\u00e7aise","volume":"80","author":"Go\u00ebb","year":"2013","journal-title":"Rev Rhum"},{"key":"2021121109425183300_rkab092-B8","first-page":"w14159","article-title":"Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases","volume":"145","author":"B\u00fchler","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"2021121109425183300_rkab092-B9"},{"key":"2021121109425183300_rkab092-B10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","article-title":"Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake","volume":"9","author":"Malhi","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2021121109425183300_rkab092-B11","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2021121109425183300_rkab092-B12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11908-011-0183-y","article-title":"TNF-\u03b1 antagonists and immunization","volume":"13","author":"Visser","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"2021121109425183300_rkab092-B13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","article-title":"Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts","volume":"133","author":"Shearer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2021121109425183300_rkab092-B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021121109425183300_rkab092-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tay080","article-title":"Measles cases hit record high in Europe in 2018","volume":"25","author":"Leong","year":"2018","journal-title":"J Travel Med"},{"key":"2021121109425183300_rkab092-B16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/infdis\/jiv060","article-title":"Response to hepatitis A vaccination in immunocompromised travelers","volume":"212","author":"Garcia Garrido","year":"2015","journal-title":"J Infect Dis"},{"key":"2021121109425183300_rkab092-B17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","article-title":"An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression \u2013 a prospective, open-label, multi-center study","volume":"21","author":"Rosdahl","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"2021121109425183300_rkab092-B18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5588\/ijtld.13.0644","article-title":"The \u2018either test positive\u2019 strategy for latent tuberculous infection before anti-tumour necrosis factor treatment","volume":"18","author":"Jung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021121109425183300_rkab092-B19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2021121109425183300_rkab092-B20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"B\u00e9lard","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab092\/41363684\/rkab092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab092\/41723593\/rkab092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab092\/41723593\/rkab092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T09:43:10Z","timestamp":1639215790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab092\/6445001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab092","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab092"}}